Survival-Gated Metabolic Reactivation of Mechanically Injured Human Hair Follicles

A translational thesis centred on adipocyte lipolysis, monounsaturated fatty-acid signalling, matrix mechanics, microneedling and red-light photobiomodulation

Hypothesis • evidence map • reproducible experimental programme • AI-directed discovery charter

Prepared for scientific evaluation and independent reproduction

Version 1.0

Generated: 2026-07-14T16:04:27.079264+00:00

Status: translational research proposal; not a clinical or self-treatment protocol

Core conclusion: plausible reactivation of damaged but surviving follicles; unresolved rescue of severely compromised follicles; no current evidence of de novo human follicle creation in mature scar.

Document control and scope

This document is a scientist-facing hypothesis and protocol framework. It does not establish that any intervention is safe or effective in humans. It intentionally avoids a home-use formulation or treatment schedule.

All proposed concentrations, optical exposures and procedural settings are laboratory starting points for ex-vivo calibration. Human use would require formulation toxicology, regulatory review, ethics approval and a clinician-led protocol.

Harvard-style author–date citations are used. Primary research and official dataset records are prioritised; anecdotal reports are explicitly labelled as such.

Contents

Abstract

Repeated hair pulling can produce a continuum from reversible cycling disturbance to irreversible follicular destruction and scar replacement. This thesis proposes a survival-gated metabolic-reactivation hypothesis: monounsaturated fatty acids (MUFAs), particularly oleic acid and palmitoleic acid, may reactivate mechanically injured human hair follicles only when epithelial stem/progenitor cells and the epithelial–mesenchymal follicular architecture remain viable. The hypothesis is anchored in Tai et al. (2025), who reported in mice that injury-induced macrophage signalling stimulated dermal-adipocyte lipolysis, released MUFAs, enabled CD36-dependent uptake by epithelial hair-follicle stem cells, and activated a PGC-1α–fatty-acid-oxidation programme associated with mitochondrial biogenesis and anagen entry. A related mouse study found that topical oleate or palmitate accelerated anagen, while a reported single-person thigh self-test provides only anecdotal human plausibility rather than controlled evidence.

The thesis integrates this metabolic pathway with evidence that human hair-follicle behaviour is constrained by progenitor survival, dermal-sheath mechanics, mechanosensitive calcium signalling and the composition and stiffness of the perifollicular matrix. It predicts three biologically distinct states: viable/minimally fibrotic follicles that may respond to MUFA activation; viable/partially fibrotic follicles that may require both metabolic activation and matrix remodelling; and scar-dominant regions where current evidence does not support de novo human follicle creation. Microneedling is therefore treated as a timing- and dose-dependent experimental perturbation that may remodel matrix or enhance delivery but may also intensify injury. Red-light photobiomodulation (PBM) is treated as a separate metabolic adjunct with a potentially biphasic dose response. “Collagen treatment” is defined as normalisation of collagen organisation, turnover, cross-linking and stiffness—not supplementation.

A sequential programme is proposed: computational reproduction of the Tai datasets; cross-species target validation; a calibrated human ex-vivo repeated-mechanical-injury model; factorial testing of MUFAs, vehicles, PBM and staged microneedling; causal perturbation of CD36, PPARGC1A and CPT1A; compartment-resolved pharmacokinetics; independent replication; and only then regulated human studies. The thesis also specifies an AI-directed discovery system that maintains a frozen claim ledger, reanalyses raw datasets, runs competing-mechanism tournaments, selects experiments by expected information gain, and treats every conclusion as provisional until its stated falsifier has been tested. The central conclusion is deliberately limited: the pathway is plausible for thickening or reactivating damaged but surviving follicles; it is unresolved for severely compromised follicles and unsupported for follicles already replaced by mature scar.

Key proposition in one table

Tissue state	What remains	What this thesis predicts	Required proof
Viable / minimally fibrotic	Follicle mini-organ and progenitors largely preserved	MUFA activation may thicken/reactivate; PBM may potentiate	Vehicle-controlled organised growth and causal CD36–PGC-1α–CPT1A engagement
Viable / partially fibrotic	Follicle survives inside stiff/inflamed matrix	Activation may require matrix normalisation; staged needling is testable	Growth plus reduced pathological stiffness without added inflammation/fibrosis
Scar-dominant / follicle absent	Follicular architecture replaced by fibrous tissue	Activation treatments probably have no substrate to reactivate	Histological proof of a new organised follicle; scar softening alone does not count

1. Research question and central thesis

The translational question is not whether fatty acids can make mouse hair grow. It is whether a defined fatty-acid signalling pathway can restore organised, durable behaviour in human follicles damaged by repeated mechanical traction, and whether the answer depends on how much follicular structure survives.

The central thesis is: topically or locally delivered oleic acid and/or palmitoleic acid can reactivate mechanically injured human hair follicles through CD36-dependent uptake and PPARGC1A/PGC-1α–CPT1A-dependent fatty-acid oxidation, but only when a viable epithelial stem/progenitor compartment and functional dermal papilla/sheath remain. Matrix stiffness, collagen architecture, inflammation and delivery act as gates on this response. Low-fluence PBM may potentiate metabolic reactivation; staged microneedling may assist selected partially fibrotic tissue through remodelling or delivery, but either may fail or cause harm at an inappropriate dose or time.

This is a mechanistic hypothesis, not a clinical recommendation. It deliberately separates reactivation of an existing follicle from restoration of a severely disrupted follicle and from true de novo follicle neogenesis. Those are different biological achievements and require different evidence.

2. Why follicle survival is the decisive variable

Human hair follicles are mini-organs maintained by interactions among epithelial stem cells in the bulge, activated progenitors, outer-root-sheath and matrix keratinocytes, dermal papilla cells, connective-tissue sheath, vasculature, immune cells, nerves, sebaceous structures and surrounding adipose tissue. Human bulge cells can be enriched using markers including CD200, while KRT15 and related markers identify stem-cell-enriched compartments (Ohyama et al., 2006). The presence of a stem-cell marker alone is insufficient: productive hair cycling requires conversion of quiescent cells into progenitors and coordinated epithelial–mesenchymal organisation.

Garza et al. (2011) found that bald androgenetic-alopecia scalp retained KRT15-high stem cells but showed depletion of CD200-rich and CD34-positive progenitor populations. Although androgenetic alopecia is not traction injury, this result is important because it demonstrates a potentially recoverable intermediate state: a follicle can retain a stem-cell reservoir while failing to generate adequate progenitors. The Tai pathway could plausibly address such a metabolic activation defect, but this remains to be demonstrated in mechanically injured human tissue.

Traction alopecia is clinically biphasic. Early lesions may be non-scarring and potentially reversible when traction stops, whereas prolonged or severe traction can become permanent and scarring (Ngwanya et al., 2019). Late disease may contain fibrous tracts in place of terminal follicles. An intervention that improves shaft production from a surviving follicle cannot be assumed to reconstruct a follicle that no longer exists. Accordingly, all experiments must stratify tissue by follicular survival rather than pool thinning, partial fibrosis and scar replacement into a single category.

3. Anchor mechanism: the Tai macrophage–adipocyte–MUFA pathway

Tai et al. (2025) reported that cutaneous injury in mice recruited macrophage activity within dermal adipose tissue and promoted adipocyte lipolysis. Released free fatty acids acted as metabolic signals to epithelial hair-follicle stem cells. The proposed downstream sequence included CD36-mediated fatty-acid uptake, PGC-1α activation, increased fatty-acid oxidation and mitochondrial biogenesis, followed by exit from quiescence and hair regeneration.

The study is stronger than a single gross-photography observation because it used genetic, pharmacological, transcriptomic and spatial approaches, and because public datasets permit independent reanalysis. GSE239986 directly compares ethanol vehicle, C18:1 and C18:0 in sorted mouse hair-follicle stem cells, although there are only two biological replicates per group. GSE239988 provides an injury time course, GSE295605 examines injury with and without an anti-inflammatory condition, and GSE295606 provides spatial transcriptomics. These resources make the mechanism testable but do not remove the species and sample-size limitations.

The reported self-application of fatty acids dissolved in alcohol to Professor Sung-Jan Lin’s thigh for approximately three weeks is not part of a controlled clinical experiment. It lacks randomisation, blinding, an untreated or vehicle-matched comparator, objective hair counts, compartment dose measurements and scalp pathology. It should be recorded as a human plausibility observation and nothing more. It cannot establish efficacy in mechanically damaged or scarred scalp.

Pan et al. (2025) independently reported that topical oleate or palmitate accelerated anagen onset in mouse models. Their human-cell experiments are also cautionary: palmitate induced inflammatory mediators in monocytes, whereas oleate produced little response in that assay. The result supports fatty-acid specificity and the need to separate metabolic activation from inflammation rather than treating all fatty acids as equivalent.

4. Human translation: conserved targets and important mismatches

The adipocyte niche is relevant to hair cycling beyond the Tai study. Festa et al. (2011) showed that adipocyte-lineage cells contribute to the skin stem-cell niche and can drive hair cycling in mice. PPARγ-dependent lipid biology is also connected to follicular integrity: hair-follicle-stem-cell-specific PPARγ deletion produced a scarring-alopecia-like phenotype in mice (Karnik et al., 2009). These findings make lipid metabolism biologically credible, but they do not prove that exogenous MUFAs repair traction-injured human follicles.

Human target validation must therefore be cell-type and state specific. CD36, PPARGC1A, CPT1A, mitochondrial respiratory genes and fatty-acid-oxidation capacity should be measured in human bulge/progenitor, outer-root-sheath, matrix, dermal-papilla, sheath, macrophage and adipocyte populations. Expression in healthy human scalp is not enough: the pathway must remain functional after repeated mechanical injury and in the presence of early fibrosis.

Species mismatch is especially important in wound healing. Adult mice can form new follicles after particular large wounds, whereas adult human wounds usually heal by fibrosis and do not routinely regenerate appendages. Wnt-dependent wound-induced hair-follicle neogenesis and Hedgehog-driven conversion of mouse wound fibroblasts into an inductive state are powerful mechanistic demonstrations, but they cannot be treated as evidence that topical MUFAs, needling or light recreate human follicles in mature scars (Ito et al., 2007; Lim et al., 2018).

5. Mechanical injury, collagen and the fibrotic gate

Repeated traction is not only an epithelial insult. It changes the mechanical environment of the follicle and can activate fibroblasts, alter extracellular-matrix turnover and progressively replace specialised tissue with scar. The relevant collagen outcome is therefore not “more collagen”. It is restoration of a compliant, normally organised, appropriately cross-linked matrix with balanced synthesis and degradation.

Chen et al. (2021) demonstrated in large-animal wounds and human fibroblast systems that mechanical forces can push fibroblasts toward ERK–YAP-driven pro-fibrotic states, whereas disruption of focal-adhesion mechanotransduction shifted tissue toward more regenerative behaviour. This supports the general proposition that force sensing and matrix stiffness can determine whether injured skin heals by regeneration or fibrosis. It does not identify a clinically ready treatment for traction alopecia.

Li et al. (2026) used human scalp single-cell and spatial approaches to implicate abnormal connective-tissue-sheath contraction in androgenetic alopecia. Hypercontractility activated PIEZO1, raised intracellular calcium, impaired mitochondria and promoted progenitor apoptosis; ex-vivo pathway modulation improved hair growth. The indication differs from mechanical pulling, but the study provides direct human evidence that sheath mechanics can suppress follicular growth through a mechanosensitive mitochondrial pathway.

A small human pilot study found that transplanted anagen follicles could remodel surrounding mature scar tissue (Plotczyk et al., 2023). This is evidence that a living follicle can alter its

matrix; it is not evidence that matrix remodelling alone recreates a missing follicle. The direction of causality matters: surviving or transplanted follicular tissue may be an active remodelling organ.

6. Microneedling as a conditional perturbation

Microneedling must not be modelled as a single generic hair-growth treatment. In this programme it has three separable roles: controlled injury that may engage immune–adipocyte signalling; mechanical remodelling of a partial fibrotic cuff; and enhancement of topical delivery. Each role predicts different biomarkers and timing effects.

Microneedling studies in androgenetic alopecia have reported benefits, particularly in combination regimens, but the evidence is heterogeneous and indication-specific. Dhurat et al. (2013) reported improved outcomes with microneedling plus minoxidil in a pilot randomised evaluator-blinded study, whereas other studies have found limited benefit from isolated needling. None establishes reversal of traction-induced perifollicular fibrosis.

A three-dimensional human skin model showed that microneedling changed inflammatory and matrix-remodelling programmes, including COL3A1, COL8A1 and TIMP3 (Schmitt et al., 2018). The model lacked complete follicles, vasculature and the full immune environment, so it cannot determine whether these changes help or harm an injured follicle. Because microneedling can increase collagen synthesis as part of wound repair, it could theoretically worsen a stiff fibrotic niche if the dose, interval or tissue state is wrong.

The decisive design is timing factorialisation. Immediate MUFA application after needling tests enhanced delivery but is maximally confounded by barrier disruption and irritation. Delayed application after objectively measured barrier recovery tests whether remodelling creates a more permissive niche without relying on acute permeability. Sham needling, needling alone, vehicle controls and direct tissue concentration measurements are essential.

7. Red-light photobiomodulation as a distinct metabolic adjunct

Red-light PBM is proposed as a downstream metabolic adjunct rather than as proof of the fatty-acid mechanism. Yang et al. (2021) exposed isolated human anagen follicles to 650-nm red light. A 0.8 J/cm² condition increased shaft elongation and proliferation and delayed anagen-to-catagen transition, whereas 1.6 J/cm² did not produce the same significant shaft-growth result. This small ex-vivo study supports a non-linear dose response and provides a reference condition, not a validated treatment for traction injury.

High-fluence red light must be treated as a separate hypothesis. Austin et al. (2021) found that much higher fluences altered human dermal-fibroblast transcriptomes, reduced proliferation and collagen-associated behaviour, and increased matrix-degrading programmes including MMP1. These exposures are orders of magnitude different from low-fluence hair-follicle PBM. Combining them under the label “RLT” would make causal interpretation impossible.

The principal PBM prediction is an interaction: if MUFAs and low-fluence PBM converge on mitochondrial competence, the combination should exceed both monotherapies in viable injured follicles, with evidence of improved oxidative metabolism but no excess reactive oxygen species, apoptosis, fibroblast activation or inflammatory signalling. If the combination only increases short-term Ki67 without organised shaft output or durability, the hypothesis is not supported.

8. Testable hypotheses, predictions and falsifiers

The following hypotheses are predeclared. Advancement is based on predicted observations and falsifiers, not on narrative plausibility.

H1. Survival-gated efficacy

Prediction	**Oleic acid and/or palmitoleic acid will increase organised shaft production in mechanically injured human follicles that retain bulge/progenitor and dermal-papilla architecture, but not in follicle-absent scar.**
Expected evidence	Response will correlate with CD200/KRT15/CD34 preservation and baseline viability.
Falsifier	No benefit over matched vehicles in viable injured follicles, or apparent regrowth occurs in scar without histological follicle structures.

H2. CD36 dependence

Prediction	**MUFAs require CD36-mediated uptake in human follicular epithelial cells.**
Expected evidence	MUFA uptake and response will fall after orthogonal CD36 perturbation.
Falsifier	CD36 perturbation does not reduce uptake, metabolic target engagement or organised growth.

H3. PGC-1α/CPT1A/FAO mediation

Prediction	**MUFA response requires PPARGC1A/PGC-1α and CPT1A-linked fatty-acid oxidation.**
Expected evidence	MUFAs will increase FAO flux, mitochondrial mass, oxygen consumption and downstream gene programmes before shaft growth.
Falsifier	Organised growth occurs without pathway activation, or pathway inhibition does not attenuate response.

H4. Fatty-acid specificity

Prediction	**Oleate and palmitoleate will outperform saturated fatty-acid comparators after vehicle and delivered-dose matching.**
Expected evidence	C18:1 and C16:1 will produce a distinct response from C18:0/C16:0.
Falsifier	Saturated controls perform equally or better, suggesting non-specific irritation or energy provision.

H5. Fibrotic gating

Prediction	**Matrix stiffness and collagen organisation will predict reduced MUFA response independently of follicle viability.**
Expected evidence	High AFM stiffness, aligned SHG collagen, α-SMA and LOX activity will identify poor responders.
Falsifier	Response is unrelated to matrix state after controlling for target expression and delivered dose.

H6. PBM synergy

Prediction	**Low-fluence 650-nm PBM will potentiate MUFA-driven mitochondrial reactivation in viable follicles.**
Expected evidence	Combination effect exceeds both monotherapies with positive interaction term.
Falsifier	Combination does not exceed both monotherapies or increases ROS/apoptosis/fibrosis.

H7. Microneedling timing

Prediction	**Delayed, calibrated microneedling may aid partially fibrotic follicles by remodelling matrix; immediate application mainly changes penetration and irritation.**
Expected evidence	Delayed needling+MUFA improves matrix and follicle endpoints without disproportionate barrier injury.
Falsifier	Benefit is fully explained by higher tissue dose, or needling increases stiffness, α-SMA, inflammation or apoptosis.

H8. Durability

Prediction	**A true rescue will persist beyond temporary anagen entry.**
Expected evidence	Follicles will retain organised cycling, shaft calibre and progenitor competence during extended culture or graft follow-up.
Falsifier	Only transient shaft elongation occurs, followed by cycle failure, progenitor depletion or progressive fibrosis.

H9. Scar remodelling is not neogenesis

Prediction	**Interventions may soften scar without recreating a follicle.**
Expected evidence	Matrix metrics may improve in scar-dominant tissue while follicle markers and organised shafts remain absent.
Falsifier	Scar improvement is incorrectly counted as hair regeneration without proof of new follicular architecture.

9. Reproducible experimental programme

The programme is sequential. It should not begin with a multi-component topical combination in people. Each stage has a predeclared advancement gate and produces a frozen evidence package containing raw data, code, environment, parameters, deviations and negative results.

Stage 1 — computational reproduction. Download all processed and, where available, raw data for GSE239986, GSE239988, GSE295605 and GSE295606. Verify sample identities and counts; run quality control; re-estimate differential expression with methods appropriate to the small replicate numbers; perform pathway scoring for fatty-acid uptake, PPARGC1A targets, β-oxidation, oxidative phosphorylation, mitochondrial biogenesis, inflammation and fibrosis; reconstruct the temporal order of macrophage, adipocyte and follicular signals; and map spatial proximity. Results must be reported with uncertainty and sensitivity to normalisation and gene-set choice.

Stage 2 — human target atlas. Integrate public human scalp and follicle single-cell/spatial datasets with newly profiled control, recently injured and chronically traction-exposed tissue. Map orthologues and test whether CD36, PPARGC1A, CPT1A and downstream modules occur in the relevant human epithelial compartments. Avoid inferring functional activity from expression alone; add protein localisation, uptake assays and metabolic flux.

Stage 3 — calibrated ex-vivo mechanical injury. Obtain de-identified human scalp tissue under institutional ethics approval and informed consent, preferably from surgical waste. Isolate intact anagen follicles and matched follicular units. Use a force-controlled microactuator to create a donor-specific mild, moderate and severe repeated-traction series. Because a validated human pulling model does not yet exist, the pilot must calibrate injury by phenotype rather than assume a universal force: viability, sheath disruption, catagen shift, mitochondrial stress, inflammatory response and absence/presence of irreversible rupture should define the strata. Record the full force–displacement trace for every unit.

Stage 4 — direct biochemical screen. In isolated follicle organ culture, test BSA-conjugated oleate and palmitoleate across a predeclared micromolar range such as 10, 30, 100 and 300 µM, with molar BSA controls, saturated-fatty-acid comparators and oxidation monitoring. These concentrations are laboratory starting points, not human topical doses. Select the minimally effective, non-cytotoxic exposure using viability, target engagement and organised shaft output.

Stage 5 — topical organotypic study. Apply finite topical doses to full-thickness scalp explants using oleate, palmitoleate, defined mixtures, ethanol vehicle, non-alcohol vehicle, and saturated controls. Quantify the concentration reaching stratum corneum, viable epidermis, follicular infundibulum, deeper follicle, dermis and adipose by validated LC–MS/MS. The biological dose is the measured tissue exposure, not the nominal surface percentage.

Stage 6 — causal validation. Perturb CD36, PPARGC1A and CPT1A using at least two orthogonal methods where feasible—for example CRISPR interference/siRNA plus a blocking approach. Do not rely solely on a single pharmacological inhibitor: commonly used tools can have off-target effects, and etomoxir is particularly problematic at high concentrations. Rescue experiments should restore the target or provide an alternative substrate/pathway where biologically justified.

Stage 7 — adjunct factorials. Only after MUFA target engagement is reproduced should low-fluence PBM and microneedling be added. PBM reference arms may reproduce the 650-nm, 0.8 and 1.6 J/cm² ex-vivo conditions reported by Yang et al. (2021), with calibrated irradiance, thermal monitoring and sham illumination. Microneedling should use automated, sterile laboratory equipment, histologically verified channel depth, sham contact and at least immediate, 24-hour and 72-hour application intervals. Needle depth and timing must be selected from explant barrier and histology data, not copied into self-treatment.

Stage 8 — durability and replication. Replicate the final mechanism in an independent laboratory, then test longer-term behaviour in a humanised graft model or another ethically approved platform capable of following more than one hair-cycle transition. A short increase in shaft length is not sufficient.

10. Experimental design and statistical analysis

The experimental unit is the donor, not the individual follicle. Follicles are nested technical/biological subsamples within donor tissue. Analyses should use mixed-effects or Bayesian hierarchical models with donor-level random effects, predeclared treatment contrasts and explicit interaction terms for injury state, fibrosis state, treatment, vehicle, PBM and microneedling timing.

A small pilot should estimate donor-level variance, within-donor correlation and attrition before a confirmatory power calculation. The confirmatory study should preregister one primary endpoint—recommended as organised shaft output incorporating elongation, calibre and matrix proliferation—plus a limited set of mechanistic co-primary or key secondary endpoints. Multiplicity across transcriptomic and biomarker panels should be controlled using false-discovery-rate procedures or a hierarchical testing plan.

Randomisation should occur within donor blocks. Histology, trichometric measurements and image analysis should be blinded. Image segmentation models must be locked before group labels are revealed. Exclusion criteria—damaged dissection, culture contamination, pre-existing dystrophy, failed delivered-dose measurement—must be defined before analysis. Missing data

and failed cultures should remain visible in the CONSORT-style flow diagram rather than silently removed.

The first screen should be fractional and sequential rather than attempt all combinations at once. A defensible core includes recovery, ethanol vehicle, non-alcohol vehicle, oleate, palmitoleate, saturated fatty-acid control, low-fluence PBM, and oleate/palmitoleate plus PBM. Microneedling arms should be restricted to the partial-fibrosis stratum and introduced only after barrier recovery and baseline matrix metrics are measurable.

11. Outcome measures and decision rules

Primary biological efficacy: organised hair-shaft elongation and calibre; matrix Ki67; maintenance of anagen morphology; coherent dermal-papilla and sheath architecture; and, in long-duration systems, competence to re-enter a subsequent productive cycle.

Target engagement: fatty-acid uptake; CD36 localisation; PPARGC1A/PGC-1α protein and transcriptional activity; CPT1A; acyl-carnitine profiles; stable-isotope fatty-acid oxidation; oxygen-consumption rate; ATP; mitochondrial mass; mtDNA copy number; membrane potential; and reactive oxygen species.

Survival state: KRT15, KRT19, CD200, CD34 and LGR5 where anatomically appropriate; cleaved caspase-3; TUNEL; live/dead imaging; dermal-papilla identity; and loss of follicular openings or replacement by fibrous tracts.

Matrix and mechanics: COL1A1/COL3A1 ratio, collagen fibre orientation by second-harmonic generation, hydroxyproline, LOX/LOXL activity, MMP/TIMP balance, α-SMA/ACTA2, phospho-MLC2, FAK/YAP activity, AFM stiffness and tissue contraction.

Inflammation and barrier: macrophage density and state, TNF, IL1B, IL6, CCL2, relevant SAA orthologue biology, transepidermal water loss, barrier-recovery time and histological irritation. An increase in hair-related endpoints accompanied by progressive fibrosis or destructive inflammation is not an acceptable success.

Advancement requires all of the following: superiority to both ethanol and non-alcohol vehicles; objective target engagement; dependence on the proposed pathway; organised rather than dysplastic output; no material worsening of inflammation/fibrosis; reproducibility across donors; and independent replication.

12. Formulation, delivery and compartment dose

Oleic acid is itself a well-known penetration enhancer and can disrupt stratum-corneum lipid organisation. Human-skin studies show time-dependent barrier effects, including changes in transepidermal water loss and electrical impedance (Touitou et al., 2002; Kováčik et al., 2023). Ethanol can also change solubility, evaporation, barrier structure and follicular delivery. Therefore, an alcohol-dissolved self-test cannot distinguish metabolic activity from penetration or irritation.

Formulation development should use a quality-by-design approach. Critical material attributes include fatty-acid identity, isomeric purity, oxidation products, water content and excipient compatibility. Critical process parameters include mixing, temperature, light/oxygen exposure and container closure. Critical quality attributes include assay, peroxide value, droplet/particle state where applicable, viscosity, evaporation rate, microbiological quality and delivered-dose reproducibility.

A mechanistically valid formulation must deliver a reproducible concentration to the relevant follicular compartment without causing barrier injury that itself drives inflammation. Franz-cell or diffusion-cell studies, imaging mass spectrometry and follicular microdissection LC–MS/MS can estimate distribution. A physiologically based skin/follicle model should be fitted to these data and propagate uncertainty in diffusion, partitioning, metabolism and evaporation.

13. Hazard, ethics and regulatory controls

Risk controls are part of reproducibility. A result obtained under uncontrolled oxidation, barrier injury, optical heating or pseudoreplication is not mechanistically interpretable.

Hazard	Why it matters	Minimum controls
Human scalp tissue	Potential exposure to blood-borne pathogens; privacy and consent risks	Institutional ethics approval; consent for research use; coded specimens; BSL-2 practices; vaccination and exposure plan; validated decontamination.
Oleic/palmitoleic and saturated fatty acids	Irritation, barrier disruption, oxidation products, variable purity	Supplier certificate and SDS; fresh protected aliquots; oxidation testing; dose-escalation in tissue; no uncontrolled human application.
Ethanol and solvents	Flammability, inhalation, irritation, major vehicle confounding	Flammable storage; fume extraction where appropriate; ignition control; exact concentration and evaporation logs; vehicle-only arms.
Microneedling / sharps	Sharps injury, contamination, tissue tearing, added inflammation or scarring	Automated sterile laboratory system; sharps SOP; histological depth verification; sham control; do not extrapolate to home use. FDA has not cleared microneedling devices for hair-loss treatment.
Red-light PBM	Eye exposure, thermal artefact, incorrect delivered fluence, biphasic response	Calibrated power meter; eyewear and beam controls; temperature logging; sham illumination; report wavelength, irradiance, fluence, pulse and distance.
Gene perturbation and inhibitors	Off-target effects, toxicity, false causal attribution	Two orthogonal perturbations; dose-response; rescue; off-target profiling; avoid interpreting single inhibitor as proof.
Large omics datasets	Batch effects, pseudoreplication, data leakage and selective reporting	Donor-aware modelling; locked pipelines; blind labels; versioned environments; full negative-result registry; external reproduction.

Hazard	Why it matters	Minimum controls
Future human study	Unknown irritation, scarring, systemic exposure and psychological vulnerability	Only after ex-vivo and toxicology gates; regulator and IRB review; dermatologist-led diagnosis; stopping rules; no enrolment while active pulling remains uncontrolled without appropriate support.

14. Evidence grading and present conclusion

High confidence: continuing traction is causally harmful; early traction-related loss may be reversible while late scar replacement may be permanent; viable follicular architecture is necessary for ordinary reactivation; vehicle and barrier effects must be controlled; and matrix mechanics are biologically relevant to fibrotic healing.

Moderate mechanistic confidence in mice: injury can engage adipocyte lipolysis and fatty-acid signalling to activate follicular stem cells; MUFAs can trigger hair growth in mouse skin; adipocyte-lineage cells participate in the follicular niche; and lipid-regulatory pathways are important for follicular integrity.

Low-to-moderate translational plausibility: the relevant metabolic pathway is likely present in some human follicular cells, and human follicles can respond to metabolic and photobiomodulatory stimuli ex vivo. Direct evidence after repeated mechanical injury is absent.

Very low clinical confidence: no controlled human trial demonstrates that topical oleic/palmitoleic acid repairs traction- or pulling-injured scalp follicles. The thigh anecdote is uncontrolled. No evidence demonstrates creation of new human follicles in mature scar using MUFAs, microneedling or RLT.

The justified conclusion is therefore narrow but useful: the pathway deserves priority testing as a means of thickening or reactivating damaged but structurally surviving follicles. The programme cannot currently answer whether severely compromised follicles can be rescued, and it predicts failure in tissue where the follicular mini-organ has been fully replaced by mature scar—unless a separate neogenesis mechanism is discovered.

15. AI-directed scientific discovery programme

An AI cannot prove a biological therapy in the same formal sense that a theorem can be proved. Biology is stochastic, context dependent and experimentally underdetermined. It can, however, operate under theorem-like proof obligations: every mechanistic claim must be linked to primary evidence, executable analysis, a quantitative prediction, a falsifying observation and an independent replication requirement.

The proposed system uses seven cooperating roles: an evidence curator; a raw-data engineer; a cross-species cell-state mapper; a causal-network and metabolic modeller; a formulation and tissue-pharmacokinetic modeller; a Bayesian experiment planner; and an adversarial

reproducibility auditor. No agent is allowed to change the success definition after seeing the result.

The system begins with a frozen hypothesis ledger. It performs a blind discovery pass on human mechanical-injury, wound, fibrosis, follicle and metabolic data; freezes the resulting causal graph; then unblinds the Tai/Pan evidence and records which elements were independently predicted. It continuously runs a competing-mechanism tournament including mechanical unloading, sheath contraction/PIEZO1, TGF-β/IL-11, FAK/YAP, immune resolution, Wnt/Hedgehog neogenesis, vascular support, progenitor survival, MUFA metabolism, PBM and microneedling.

The experiment planner selects the next study by expected information gain, not by the probability of producing a positive headline. For example, a CD36 perturbation experiment may be more valuable than another dose screen because it discriminates the proposed mechanism from nonspecific irritation. The planner is constrained by ethics, material availability, cost, donor diversity and the rule that human exposure cannot be proposed before all translation gates are passed.

Every run produces a machine-readable claim certificate: claim identifier; exact wording; evidence sources; dataset hashes; code commit; parameters; result; uncertainty; alternative explanations; falsifier status; and next discriminating experiment. Contradictory results remain in the ledger and reduce confidence.

16. Discussion

The value of centring the Tai study is that it provides a specific, perturbable chain rather than a vague claim that “oils nourish hair”. Its weakness is that a compelling mouse mechanism can tempt premature formulation and self-experimentation. The correct translation is to preserve the chain—injury context, adipocyte signal, MUFA uptake, mitochondrial activation and stem-cell response—while aggressively testing which links survive in human mechanically injured tissue.

Microneedling and PBM are not automatically complementary. Microneedling changes barrier permeability, inflammation and matrix remodelling; PBM can change mitochondrial and fibroblast behaviour in dose-dependent ways. A combination can appear successful while its causal explanation is wrong. Only factorial controls and compartment-dose measurements can determine whether the combination truly rescues follicular biology.

The thesis also changes the meaning of “dead follicle”. The useful categories are not alive versus dead but a spectrum: quiescent but intact; progenitor-deficient; metabolically compromised; partially disrupted and fibrotically constrained; and structurally absent. Future imaging and molecular classifiers should assign tissue to these states before treatment. This staging problem may be as important as the treatment itself.

Finally, the programme preserves a route to a more ambitious objective: de novo follicle regeneration. If scar-dominant tissue fails all activation approaches, the AI system should not repeatedly optimise the same MUFA formulation. It should switch problem class to epithelial–

mesenchymal organogenesis, including Wnt/Hedgehog, dermal-papilla inductivity, tissue engineering and scar-to-regenerative fibroblast conversion. That is a different research programme with substantially higher evidential and safety requirements.

17. Conclusions

The Tai macrophage–adipocyte–MUFA pathway is a credible lead hypothesis for reactivating damaged but surviving human hair follicles. It is supported by a mechanistic mouse study, public omics datasets, independent mouse anagen findings and broader evidence that adipocyte and lipid-metabolic pathways participate in the hair-follicle niche.

Translation is gated by human follicle survival, pathway competence, matrix mechanics and formulation delivery. Microneedling may be useful only as a calibrated, staged adjunct in partial fibrosis. Low-fluence PBM may support mitochondrial activation, but the interaction must be demonstrated rather than assumed. Collagen must be measured and remodelled; adding collagen is not the objective.

The key unresolved experiment is a donor-aware human ex-vivo repeated-mechanical-injury study with matched vehicles, causal pathway perturbation, compartment-resolved fatty-acid exposure and separate viable, partially fibrotic and follicle-absent strata. Until that experiment succeeds and is independently replicated, the hypothesis remains promising but unproven.

The attached AI protocol converts the research question into a falsifiable closed loop. Its purpose is not to generate confidence by repetition; it is to discover where the hypothesis fails, identify the narrow responder state if one exists, and redirect the programme toward neogenesis only if activation of surviving follicles is insufficient.

17.1 Operational AI charter

- Never treat agreement with the Tai paper as confirmation. Maintain at least ten competing mechanisms and update all of them after every experiment.
- Freeze the claim ledger, evidence corpus, code commit, environment, random seed and primary endpoints before unblinding each result.
- For every positive finding, generate at least three alternative explanations: vehicle/penetration, irritation/inflammation, spontaneous recovery, selection bias, image-analysis leakage, batch effects or a different metabolic pathway.
- Require orthogonal causal perturbation for CD36, PPARGC1A and CPT1A; require rescue where feasible.
- Stratify by follicle survival and fibrosis before calculating a treatment effect. Never average follicle-absent scar together with viable follicles.
- Choose the next experiment by expected information gain and ethical feasibility, not by expected positivity.
- Stop or redirect the programme if the predeclared falsifier is met. Do not move the goalposts.

- Prohibit proposed personal application, clinical dose or combination schedule until the translation-gate certificate is complete.

Appendix A. Core experimental arms

ID	Arm	Intervention	Stratum	Purpose
A01	Recovery control	Unloading + vehicle/sham only	All viable strata	Separates spontaneous recovery
A02	Ethanol control	Ethanol vehicle matched to Tai formulation	All viable strata	Separates alcohol penetration/irritation
A03	Non-alcohol vehicle control	Alternative vehicle without MUFA	All viable strata	Separates vehicle effects
A04	Oleic acid	Pure C18:1 in validated vehicle	Minimal/partial fibrosis	Tests principal MUFA
A05	Palmitoleic acid	Pure C16:1 in validated vehicle	Minimal/partial fibrosis	Tests second MUFA
A06	MUFA mixture	C18:1+C16:1	Minimal/partial fibrosis	Tests mixture/synergy
A07	Saturated FA negative control	C18:0 or C16:0	Minimal/partial fibrosis	Specificity control
A08	Microneedling sham	Device contact without penetration	Partial fibrosis	Procedural placebo
A09	Microneedling alone	Calibrated controlled channels	Partial fibrosis	Tests remodelling/injury effect
A10	Microneedling + immediate MUFA	MUFA applied immediately after needling	Partial fibrosis	Tests delivery but highest irritation confounding
A11	Microneedling + delayed MUFA	MUFA after barrier-recovery interval	Partial fibrosis	Tests staged remodelling plus activation
A12	Low-fluence PBM	Mitochondrial-support light regime	Minimal/partial fibrosis	Tests downstream metabolic support
A13	MUFA + low-fluence PBM	MUFA plus mitochondrial-support PBM	Minimal/partial fibrosis	Core synergy hypothesis
A14	Microneedling + PBM	Staged needling and low PBM	Partial fibrosis	Tests scar remodelling plus energy support
A15	Triple staged combination	Needling -> recovery -> MUFA + PBM	Partial fibrosis	Highest-priority combination only after monotherapies
A16	Anti-fibrotic PBM	Separate higher-tissue-dose regime	Partial fibrosis	Tests matrix effect; do not conflate with A12
A17	Matrix-remodelling laboratory control	Validated anti-fibrotic/LOX–TGF-β control	Partial fibrosis	Benchmarks collagen remodelling

ID	Arm	Intervention	Stratum	Purpose
A18	Positive growth comparator	Minoxidil or accepted ex-vivo comparator	All viable strata	Assay validity
A19	Scar-dominant observation	Matched interventions in absent-follicle scar	Scar-dominant	Distinguishes scar improvement from follicle regeneration

Appendix B. Public dataset manifest

Accession	Dataset	Design	Planned analysis
GSE239986	Mouse sorted HFSC RNA-seq	EtOH vs C18:1 vs C18:0; two replicates/group	Reanalyse MUFA specificity, OXPHOS/FAO, PPARGC1A targets; underpowered for subtle effects
GSE239988	Mouse whole-skin RNA-seq	Day 0, SDS days 1/3/5; two replicates/timepoint	Time-order macrophage/adipocyte/lipolysis/stem-cell and fibrosis signatures
GSE295605	Mouse SDS time course with/without Topsym	16 samples	Test inflammation-dependence and separate regenerative from inflammatory programs
GSE295606	Mouse Visium HD spatial transcriptomics	Early pooled D0-D2 vs later pooled D3-D5	Map macrophage-adipocyte-HFSC spatial sequence; limited biological replication

Appendix C. Minimum reproducibility package

- Raw and processed data with immutable checksums and accession identifiers.
- Executable environment lockfile/container; operating system and package versions.
- Analysis scripts, notebooks and command logs; no manual spreadsheet-only transformations.
- Sample sheet containing donor, tissue state, injury calibration, treatment, batch and exclusion status.
- Blinded image-analysis model and its training/validation set; model hash and threshold settings.
- All protocol deviations, failed cultures, contamination events and negative results.
- Preregistered primary endpoint, statistical model and multiplicity plan.
- Machine-readable claim ledger and translation-gate certificate.

Appendix D. AI claim-certificate schema

claim_id: H2-CD36-dependence
claim_text: MUFA-induced organised growth requires CD36-mediated uptake

```
status: untested | supported | weakened | falsified
evidence:
  - source_id: DOI-or-accession
    evidence_type: primary-paper | raw-data-reanalysis | wet-lab
    species: mouse | human
    tissue_state: viable | partial-fibrosis | scar-dominant
prediction:
  endpoint: organised_shaft_output
  direction: decrease_after_CD36_perturbation
falsifier:
  rule: no_material_reduction_with_two_orthogonal_perturbations
analysis:
  code_commit: <git-sha>
  environment_hash: <sha256>
  dataset_hashes: []
uncertainty:
  effect_estimate: null
  interval: null
alternatives: []
next_experiment: null
```

References

Austin, E., Huang, A., Wang, J.Y., Cohen, M., Zhou, L., Liu, K.R., Wu, M., Yuan, C., Ma, Y. and Jagdeo, J. (2021) ‘Transcriptome analysis of human dermal fibroblasts following red light phototherapy’, Scientific Reports, 11, 7315. doi: 10.1038/s41598-021-86623-2.

Chen, K. et al. (2021) ‘Disrupting biological sensors of force promotes tissue regeneration in large organisms’, Nature Communications, 12, 5256. doi: 10.1038/s41467-021-25410-z.

Dhurat, R., Sukesh, M.S., Avhad, G., Dandale, A., Pal, A. and Pund, P. (2013) ‘A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study’, International Journal of Trichology, 5(1), pp. 6–11. doi: 10.4103/0974-7753.114700.

Faghihi, G., Nabavinejad, S., Mokhtari, F., Fatemi Naeini, F. and Iraji, F. (2021) ‘Microneedling in androgenetic alopecia; comparing two different depths of microneedles’, Journal of Cosmetic Dermatology, 20(4), pp. 1241–1247. doi: 10.1111/jocd.13714.

Festa, E., Fretz, J., Berry, R., Schmidt, B., Rodeheffer, M., Horowitz, M. and Horsley, V. (2011) ‘Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling’, Cell, 146(5), pp. 761–771. doi: 10.1016/j.cell.2011.07.019.

Francoeur, M.L., Golden, G.M. and Potts, R.O. (1990) ‘Oleic acid: its effects on stratum corneum in relation to transdermal drug delivery’, Pharmaceutical Research, 7(6), pp. 621–627. PMID: 2367329.

Garza, L.A. et al. (2011) ‘Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells’, Journal of Clinical Investigation, 121(2), pp. 613–622. doi: 10.1172/JCI44478.

Ito, M. et al. (2007) ‘Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding’, Nature, 447, pp. 316–320. doi: 10.1038/nature05766.

Karnik, P. et al. (2009) ‘Hair follicle stem cell-specific PPARγ deletion causes scarring alopecia’, Journal of Investigative Dermatology, 129(5), pp. 1243–1257. doi: 10.1038/jid.2008.369.

Kim, H. et al. (2013) ‘Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial’, Dermatologic Surgery, 39(8), pp. 1177–1183. PMID: 23551662.

Kováčik, A., Kopečná, M., Hrdinová, I., Opálka, L., Boncheva Bettex, M. and Vávrová, K. (2023) ‘Time-dependent differences in the effects of oleic acid and oleyl alcohol on the human skin barrier’, Molecular Pharmaceutics, 20(12), pp. 6237–6245. doi: 10.1021/acs.molpharmaceut.3c00648.

Li, G. et al. (2026) ‘Single-cell transcriptomics reveals hair growth retardation mediated by aberrant connective tissue sheath contraction in male androgenetic alopecia’, Nature Communications, 17, 3252. doi: 10.1038/s41467-026-70153-4.

Lim, C.H., Sun, Q., Ratti, K. et al. (2018) ‘Hedgehog stimulates hair follicle neogenesis by creating inductive dermis during murine skin wound healing’, Nature Communications, 9, 4903. doi: 10.1038/s41467-018-07142-9.

National Center for Biotechnology Information (NCBI) (2025a) Gene Expression Omnibus: GSE239986, mouse sorted hair-follicle stem-cell RNA sequencing, ethanol versus C18:1 versus C18:0. Available at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE239986 (Accessed: 14 July 2026).

National Center for Biotechnology Information (NCBI) (2025b) Gene Expression Omnibus: GSE239988, mouse skin injury time-course RNA sequencing. Available at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE239988 (Accessed: 14 July 2026).

National Center for Biotechnology Information (NCBI) (2025c) Gene Expression Omnibus: GSE295605, mouse injury time course with and without anti-inflammatory treatment. Available at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295605 (Accessed: 14 July 2026).

National Center for Biotechnology Information (NCBI) (2025d) Gene Expression Omnibus: GSE295606, mouse skin Visium HD spatial transcriptomics. Available at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295606 (Accessed: 14 July 2026).

National Taiwan University (2026) ‘NTU develop serum restoring hair in 20 days’, NTU Lab Spotlight, updated 29 January. Available at: https://labspotlight.ntu.edu.tw/focus/229 (Accessed: 14 July 2026).

Ngwanya, R.M., Adeola, H.A., Beach, R.A., Gantsho, N., Walker, C.L., Pillay, K., Prokopetz, R., Gumedze, F. and Khumalo, N.P. (2019) ‘Reliability of histopathology for the early recognition of fibrosis in traction alopecia: correlation with clinical severity’, Dermatopathology, 6(2), pp. 170–181. doi: 10.1159/000500509.

Ohyama, M., Terunuma, A., Tock, C.L., Radonovich, M.F., Pise-Masison, C.A., Hopping, S.B., Brady, J.N., Udey, M.C. and Vogel, J.C. (2006) ‘Characterization and isolation of stem cell-enriched human hair follicle bulge cells’, Journal of Clinical Investigation, 116(1), pp. 249–260. doi: 10.1172/JCI26043.

Pan, X. et al. (2025) ‘Effect of free long-chain fatty acids on anagen induction: metabolic or inflammatory aspect?’, International Journal of Molecular Sciences, 26(6), 2567. doi: 10.3390/ijms26062567.

Plotczyk, M., Jiménez, F., Limbu, S., Boyle, C.J., Ovia, J., Almquist, B.D. and Higgins, C.A. (2023) ‘Anagen hair follicles transplanted into mature human scars remodel fibrotic tissue’, npj Regenerative Medicine, 8, 1. doi: 10.1038/s41536-022-00270-3.

Schmitt, L.C. et al. (2018) ‘Comprehensive molecular characterization of microneedling therapy in a human three-dimensional skin model’, PLOS ONE, 13(9), e0204318. doi: 10.1371/journal.pone.0204318.

Tai, K.-Y. et al. (2025) ‘Adipocyte lipolysis activates epithelial stem cells for hair regeneration through fatty acid metabolic signaling’, Cell Metabolism, 37(11), pp. 2202–2219.e8. doi: 10.1016/j.cmet.2025.09.012.

Touitou, E., Godin, B., Karl, Y., Bujanover, S. and Becker, Y. (2002) ‘Oleic acid, a skin penetration enhancer, affects Langerhans cells and corneocytes’, Journal of Controlled Release, 80(1–3), pp. 1–7. doi: 10.1016/S0168-3659(02)00004-4.

U.S. Food and Drug Administration (2025) ‘Microneedling devices: getting to the point on benefits, risks and safety’, updated 15 October. Available at: https://www.fda.gov/consumers/consumer-updates/microneedling-devices-getting-point-benefits-risks-and-safety (Accessed: 14 July 2026).

Yang, K. et al. (2021) ‘Hair growth promoting effects of 650 nm red light stimulation on human hair follicles and study of its mechanisms via RNA sequencing transcriptome analysis’, Annals of Dermatology, 33(6), pp. 553–561. doi: 10.5021/ad.2021.33.6.553.